Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2612 2023-08-23 23:01:11 |
2 format change Meta information modification 2612 2023-08-24 04:41:18 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Toledano, S.; Neufeld, G. Plexins in Cancer Cell Proliferation, Migration, and Invasivity. Encyclopedia. Available online: https://encyclopedia.pub/entry/48395 (accessed on 12 October 2024).
Toledano S, Neufeld G. Plexins in Cancer Cell Proliferation, Migration, and Invasivity. Encyclopedia. Available at: https://encyclopedia.pub/entry/48395. Accessed October 12, 2024.
Toledano, Shira, Gera Neufeld. "Plexins in Cancer Cell Proliferation, Migration, and Invasivity" Encyclopedia, https://encyclopedia.pub/entry/48395 (accessed October 12, 2024).
Toledano, S., & Neufeld, G. (2023, August 23). Plexins in Cancer Cell Proliferation, Migration, and Invasivity. In Encyclopedia. https://encyclopedia.pub/entry/48395
Toledano, Shira and Gera Neufeld. "Plexins in Cancer Cell Proliferation, Migration, and Invasivity." Encyclopedia. Web. 23 August, 2023.
Plexins in Cancer Cell Proliferation, Migration, and Invasivity
Edit

Plexins are a family of nine single-pass transmembrane receptors with a conserved GTPase activating protein (GAP) domain. The plexin family is divided into four subfamilies: Type-A, type-B, type-C, and type-D plexins. Plexins function as receptors for axon guidance factors of the semaphorin family. The semaphorin gene family contains 22 genes that are divided into eight subclasses of which subclasses three to seven represent vertebrate semaphorins. The plexins and their semaphorin ligands have important roles as regulators of angiogenesis, cancer proliferation, and metastasis. Class 3 semaphorins, with the exception of sema3E, are the only semaphorins that do not bind directly to plexins. In order to transduce their signals, they bind instead to complexes consisting of receptors of the neuropilin family and various plexins. Some plexins also form complexes with tyrosine-kinase receptors such as the epidermal growth factor receptor ErbB2, the mesenchymal epithelial transition factor receptor (MET), and the Vascular endothelial growth factor receptor 2 (VEGFR2) and, as a result, can modulate cell proliferation and tumor progression. 

semaphorins cancer plexins metastasis

1. The Plexin Receptor Family

The nine receptors of the plexin family are segregated into four subfamilies consisting of four Type-A plexins, three Type-B plexins, and single C and D plexins (Figure 1) [1]. Plexins serve as direct binding receptors for most semaphorins, which are a large family of evolutionarily conserved signaling molecules that were initially identified as axon guidance factors [2]. The extracellular domains of all plexins contain a sema domain which is also present in semaphorins and serves as an auto-inhibitory domain in the basal, dimeric, non-activated state of the receptor [3]. Once a semaphorin binds to the extracellular domain of the plexins, it induces a conformational change in the two dimerized plexins that initiates signal transduction [3][4][5]. The extracellular domains of the plexins and of the semaphorins also contain plexin-semaphorin-integrin (PSI) domains which contain eight cysteine residues and bridge the sema and immunoglobulin-plexin-transcription (IPT) domains thereby ensuring the correct formation and correct orientation of the ligand-receptor binding sites [1]. The extracellular domain of the plexin-B family receptors is unique among the plexins because it contains a conserved cleavage site for furin-like pro-protein convertases. This cleavage site is posttranslationally processed, resulting in the generation of functional soluble type B plexin extracellular domains that are able to sequester semaphorins that bind to type B plexins [6]. The intracellular domains of the plexins are characterized by the presence of a GTPase-activating (GAP) domain. The GAP domain is highly conserved throughout the plexin family. Activation of plexin signal transduction is associated with the recruitment and activation of several GTP-binding proteins, such as Rac1, Rnd1, and Rho, to the GAP domain [7]. Activation of the GAP domain also confers the deactivation of R-Ras, M-Ras, and Rap1 in all plexins [8][9][10][11]. The GAP activity toward R-Ras and M-Ras, but not toward Rap1, also requires Rnd GTPases binding to the plexin receptors [8][9][11][12]. The intracellular domains also contain putative tyrosine phosphorylation sites and a split cytoplasmic SP (sex-plexin) domain but no tyrosine kinase domain (Figure 1) [13].
Figure 1. The structure of plexins: The nine vertebrate plexins are subdivided into four type A, three type B, and one each of plexins C and D. Plexins are single-pass transmembrane receptors distinguished by the presence of a split cytoplasmic GTPase-activating protein (GAP) domain that binds small GTPases such as Rho and Rac1. The extracellular domains of all plexins contain a sema domain, PSI (Plexin, Semaphorin, Integrin) motifs, and immunoglobulin-plexin-transcription (IPT) glycine–proline (G–P)-rich motifs, which the plexins share with the tyrosine kinase receptors belonging to the MET tyrosine-kinase receptors family.
Plexin-A1 is the best-studied plexin among the vertebrate type-A plexins. Its cytoplasmatic domain was found to be critical for its ability to mediate sema3A signal transduction [13][14][15]. Following stimulation by sema3A, the Rac1 guanyl nucleotide exchange factor (GEF) FARP2 and Rac1 bind to plexin-A1, resulting in the activation of Rac1, which subsequently promotes WNT3A-induced accumulation of β-catenin in the nucleus [16]. Active Rac1 also binds to the RhoGTPase Binding Domain (RBD) of plexin-A1 and, as a result, induces a conformational change in the intracellular domain of plexA1, which enables the binding of Rnd1 to plexin-A1. Interestingly, RhoD is also able to bind to the RBD domain and can inhibit the binding of Rnd1 [17][18]. Type-A plexins also interact directly with Molecules Interacting with CasL (MICALs). The three MICAL human family members are flavoprotein oxidoreductases that oxidize actin filaments in response to stimulation with semaphorins causing their disassembly [19].
In contrast to type-A plexins, type-B plexins contain a unique C-terminal PDZ binding motif [20]. Through this domain type-B plexins associate with PDZ-RhoGEF and with Leukemia-associated RhoGEF (LARG). Rnd1 promotes this association by binding to plexin-B1 [21]. It was also found that activation of plexin-B1 by sema4D creates docking sites for the SH2 domains of phospholipase C-gamma (PLCgamma). Recruited PLCgamma subsequently then activates PDZ-RhoGEF [22]. The PDZ binding motif is also critical for the activation of the plexin-B family by RhoA, resulting in stress fiber formation [23]. Another regulator of Rho activity is p190 Rho-GTPase, which inactivates Rho upon the binding of semaphorins to plexins [24]. Unlike the type-A and Type-C plexins, plexin-D1 also possesses a PDZ binding motif [25].
Type-A and Type-B plexins associate spontaneously to form homodimers [4][5] or heterodimers [26]. Class 4–7 semaphorins bind directly to plexins. Class-3 semaphorins, with the exception of sema3E which binds directly to plexin-D1, bind to a complex consisting of a plexin receptor, and one of the two neuropilin receptors that on their own do not transduce semaphorin signals [13][27].

2. The Role of the Different Plexins in Tumor Progression

2.1. Type-A Plexins

Class-3 semaphorins transduce repulsive signals using complexes of neuropilin and type-A plexin receptors. Activation of these plexins by class-3 semaphorins as well as by class-6 semaphorins usually inhibits tumor angiogenesis, and when expressed in tumor cells, these plexins also usually inhibit tumor progression (Figure 2) (Table 1). However, this is a generalization, and their association with additional modulators can lead to opposite effects (Table 1) (Figure 3).
Figure 2. Inhibition of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to inhibit tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. In the case of sema3A, neuropilin is required in addition to a type A plexin. The intracellular domain of plexin-D1 was found to associate with the nuclear orphan receptor NR4A1, which is depicted on a yellow background. This, in turn, induces apoptosis of the breast cancer cells. The references shown at the bottom of the panels direct to the relevant manuscripts.
Table 1. Plexins and their role in various types of cancers. Shown is a summary of the effects of the various plexins and of their various ligands and associated cell surface molecules, on the behavior of various types of tumor cells. 

Plexin

Modulators of Plexin-Mediated Signal Transduction

Role

Cancer Type

Refs

Plexin-A1

Sema3A

Inhibition of

proliferation

Malignant

mesothelial cells

[28]

Sema3A,

NRP-1, Perlecan

Promotion of

metastatic

dissemination

Prostate cancer cells

[29]

Sema6D, VEGFR-2

Promotion of survival and tumor growth

Malignant

mesothelioma cells

[30]

Sema3A

Promotion of

proliferation and

glycolytic activity

Lung cancer cells

[31]

Sema3A, NRP-1

Inhibition of

proliferation

Brain tumor stem cells

[32]

Plexin-A2

 

Enhancement of

migration and invasion

Prostate cancer cells

[33]

Sema3C, NRP-1, MAOA, MET

Promotion of

perineural invasion

Prostate cancer cells

[34]

Sema3A, KIAA1199

Inhibition of apoptosis

Cervical cancer cells

[35]

 

Enabling cell

proliferation and the development of tumors

Glioblastoma

derived cells

[36]

Plexin-A3

 

Inhibition of cell

invasion

Epithelial ovarian cancer cells

[37]

Plexin-A4

Sema6B

Promotion of pro-

proliferative signals

Glioblastoma-derived cells, lung-cancer-derived cells, malignant-melanoma-derived cells

[26]

miR-564

Promotion of cell

proliferation and

migration

Non-small cell lung carcinoma cells

[38]

Plexin-B1

Sema4D

Promotion of EMT and tumor cell metastasis

Head and neck

squamous cell

carcinoma

[39]

Sema4D

Promotion of cell

invasion, proliferation, and migration

Osteosarcoma cells

[40]

Sema3C,

NRP-1/2, EGFR, ErbB2, MET

Promotion of cancer growth

Castration-resistant prostate cancer cells

[41]

TMPRSS2-ERG

Promotion of cell

migration and invasion

Prostate cancer cells

[42]

 

Promotion of cell

migration and invasion

Ovarian cancer

derived cells

[43]

 

Inhibition of breast cancer cell motility

Breast cancer cells

[44]

 

Suppression of

tumorigenesis

Primary melanoma cells

[45]

 

Inhibition of cell

proliferation

Basal cell carcinoma cells

[46]

Plexin-B2

 

Inhibition of cell

proliferation

Basal cell carcinoma cells

[46]

Sema4C, ErbB2

Promotion of

proliferation and

development of tumor metastasis

Breast cancer

derived cells

[47]

Sema4C, MET

Promotion of glioma and glioblastoma cell invasion

Glioma and

Glioblastoma cells

[48]

Angiogenin

Inhibition of tumor cell proliferation and

inhibition of tumor

development

Glioblastoma cells, breast cancer cells, and myelogenous leukemia cells

[49]

Angiogenin

Enhancement of CSC stemness and resistance to chemotherapy

Prostate cancer stem cells

[50]

Angiogenin

Promotion of

proliferation, invasion, and tumor growth

Glioblastoma cells

[51]

Circular RNA, Circ_0013958

Promotion of

proliferation,

migration, invasion, and tumor growth

Ovarian cancer cells

[52]

 

EGFR

Promotion of

proliferation,

invasiveness and tumor-forming ability by

constitutively active plexin-B2

Stem cells from

cancers from

unknown primary tumors

[53]

Plexin-B3

Sema5A

Inhibition of migration and invasion

Glioma cells

[54]

 

Inhibition of migration, invasion, and tumor metastasis

Pancreatic cancer cells

[55]

 

Promotion of cancer cell growth, cell

migration, cell invasion, and tumor progression

Triple-negative breast cancer cells

[56]

Plexin-C1

Sema7A

Inhibition of tumor progression

Melanoma cells

[57]

 

Inhibition of tumor progression

Glioma cells

[58]

Sema7A,

β1 integrin

receptors

Promotion of

metastasis

Melanoma and breast cancer cells

[59]

 

Promotion of migration and proliferation

Gastric cancer cells

[60]

Plexin-D1

P61-sema3E, ErbB2

Promotion of tumor cell invasiveness and tumor cell metastasis

Melanoma cells, lung carcinoma cells, colon

carcinoma cells

[61][62]

NR4A1

Promotion of apoptosis

Breast cancer cells

[63]

Sema3C, plexin-A2, NRP-1

Promotion of cell

survival

Glioma stem cells

[64]

Figure 3. Potentiation of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to promote tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexin or neuropilin/plexin complexes in the case of the class-3 semaphorins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. Modulators of plexin-mediated signal transduction, which interact with the plexins, such as the cell surface receptors MET, VEGFR2, and perlecan, are depicted. Other molecules that affect signal transduction by various plexins, such as angiogenin which functions as an alternative plexin-B2 ligand, and MAOA and KIAA1199, which functions as modulators of sema3C or sema3A signaling, are depicted on a yellow background. Double-headed arrows indicate association with additional cell surface receptors, such as various tyrosine-kinase receptors, which can be activated following the binding of various semaphorins to their plexin receptors to promote tumor cell proliferation and invasiveness. The references shown at the bottom of the panels direct to the relevant manuscripts.

2.2. Type-B Plexins

Type-B plexins are known to participate in the promotion of angiogenesis and tumor progression (Table 1) (Figure 3). However, they can also transduce inhibitory signals (Figure 2) (Table 1).Type-B plexins transduce the signals of class-3, class-4, and class-5 semaphorins and of other factors, such as the ribonuclease angiogenin [49] and the androgen-regulated-trans-membrane-serine protease gene [42].

2.3. Plexin-C1

Plexin-C1 functions as a receptor for sema7A [65]. It is a tumor suppressor that inhibits progression of melanomas. Plexin-C1 expression is downregulated in primary malignant melanoma as compared with melanocytic nevi and is lowest in metastatic melanoma. Sema7A binding to plexin-C1 upregulates Lim kinase II, which phosphorylates cofilin and inactivates cofilin, which inhibits tumor progression (Figure 2) (Table 1) [57]. In human glioma cells, it was observed that Growth Arrest-Specific 5 (GAS5) is a tumor suppressor which downregulates miR-222 and, as a result, upregulates plexin-C1 and inactivates cofilin, resulting in inhibition of tumor progression (Table 1) [58]. The binding of sema7A to plexin-C1 and β1 integrin receptors stimulates the expression of the Chi3l1 gene, which promotes metastasis of melanoma and breast cancer cells (Table 1) [59]. In hepatocellular carcinoma (HCC), plexin-C1 was overexpressed. The expression was correlated with the histological grade of HCC and overall survival [66][67]. Plexin-C1 was also found to be upregulated in tumors of patients with stomach adenocarcinoma as compared to non-tumor tissues. In these tumors, it was found that plexin-C1 expression is regulated by interferon regulatory factor-5 (IRF5) and that the expression is highly correlated with the presence of M2 macrophages which promote tumor progression [68][69]. In gastric cancer cells, plexin-C1 was found to be upregulated and to promote migration and proliferation of these cells through activation of epithelial to mesenchymal transition (EMT) and through induction of the expression of genes related to inflammation (Table 1) [60]. Additionally, plexin-C1 is over-expressed in hepatocellular carcinoma, and its expression is inversely correlated with overall survival [67].

2.4. Plexin-D1

Plexin-D1 is expressed aberrantly in many types of solid tumors in both tumor vessels and tumor cells [70][71]. Plexin-D1 functions as a receptor for sema3E. In contrast to other class-3 semaphorins, sema3E binds to plexin-D1 directly without the requirement for neuropilins [72]. Sema3C binds to NRP-1, which then associates with plexin-D1 in endothelial cells to activate plexin-D1, resulting in inhibition of angiogenesis [73]. Interestingly, sema3C can also activate plexin-D1-mediated signal transduction in the absence of neuropilins, provided that plexin-A4 is also co-expressed along with plexin-D1 [74]. Sema3C was also reported to activate signaling via an NRP-2/plexin-A1 complex in lymphatic endothelial cells and to inhibit lymphangiogenesis [75]. Plexin-D1 mediates inhibitory signals induced by full-length sema3E to inhibit tumor angiogenesis and tumor metastasis [62]. Sema3E is cleaved by furin-like pro-protein convertases, which are abundant in the microenvironment of tumors, to produce p61-Sema3E, a cleaved active variant of sema3E [76]. The p61-sema3E cleavage product is also able to bind to plexin-D1 and to inhibit angiogenesis, but in contrast to the full-length form also promotes the association of plexin-D1 with ErbB2. This results in the activation of ErbB2 that, in turn, promotes tumor cell invasiveness and tumor metastasis (Table 1) (Figure 3) [61][62]. Plexin-D1 expressed in breast cancer cells interacts, in the absence of sema3E, with the orphan nuclear receptor NR4A1 to induce apoptosis. Following the binding of sema3E, the interaction with NR4A1 is disrupted, enabling sema3E-induced tumor cell survival. However, it is not clear if this effect is mediated by full length or by the furin-cleaved p61-Sema3E form of sema3E (Figure 2) (Table 1) [63]. Plexin-D1 was also found to form complexes with plexin-A2 and NRP-1. Sema3C signaling via this complex promotes the survival of glioma stem cells via activation of Rac1 (Table 1) (Figure 3) [64]. Plexin-D1 may serve as a potential biomarker for cervical cancer, as it was found that it is strongly expressed in the endothelial cells of the cervical cancer samples, and there is no expression of plexin-D1 in endothelial cells derived from normal cervical tissues [77].

3. Conclusions

Plexins are a family of single-pass transmembrane receptors which have the ability to inhibit or potentiate tumor cell proliferation and invasiveness. Plexins function primarily as semaphorin receptors. Various plexins are expressed in tumor cells as well as in a variety of other cell types, which are recruited to the tumor microenvironment, such as endothelial cells. The final effects on tumor progression are, of course, an integration of all of these effects. Here only the direct effects of plexin-mediated signal transduction on the behavior of tumor cells were covered. Interestingly, the effects that given semaphorins have on the behavior of tumor cells are strongly modulated by the association of their plexin and neuropilin receptors with additional cell surface molecules. For example, sema3A,which normally inhibits tumor cell invasiveness when signaling through its plexin-A1 receptor, induces tumor cell invasiveness following the association of its plexin-A1 receptor with cell surface-associated perlecan. It is likely that in addition to the known interactions that were covered here, there are additional interactions that can also modulate plexin mediated responses of tumor cells to semaphorins. The identification of such modulating interactions is likely to become the focus of future studies.

References

  1. Hota, P.K.; Buck, M. Plexin structures are coming: Opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell Mol. Life Sci. 2012, 69, 3765–3805.
  2. Luo, Y.; Raible, D.; Raper, J.A. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993, 75, 217–227.
  3. Takahashi, T.; Strittmatter, S.M. PlexinA1 Autoinhibition by the Plexin Sema Domain. Neuron 2001, 29, 429–439.
  4. Janssen, B.J.; Robinson, R.A.; Perez-Branguli, F.; Bell, C.H.; Mitchell, K.J.; Siebold, C.; Jones, E.Y. Structural basis of semaphorin-plexin signalling. Nature 2010, 467, 1118–1122.
  5. Nogi, T.; Yasui, N.; Mihara, E.; Matsunaga, Y.; Noda, M.; Yamashita, N.; Toyofuku, T.; Uchiyama, S.; Goshima, Y.; Kumanogoh, A.; et al. Structural basis for semaphorin signalling through the plexin receptor. Nature 2010, 467, 1123–1127.
  6. Artigiani, S.; Barberis, D.; Fazzari, P.; Longati, P.; Angelini, P.; van de Loo, J.W.; Comoglio, P.M.; Tamagnone, L. Functional regulation of semaphorin receptors by proprotein convertases. J. Biol. Chem. 2003, 278, 10094–10101.
  7. Siebold, C.; Jones, E.Y. Structural insights into semaphorins and their receptors. Semin. Cell Dev. Biol. 2012, 24, 139–145.
  8. Oinuma, I.; Ishikawa, Y.; Katoh, H.; Negishi, M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 2004, 305, 862–865.
  9. Oinuma, I.; Katoh, H.; Negishi, M. Molecular dissection of the semaphorin 4D receptor plexin-B1-stimulated R-Ras GTPase-activating protein activity and neurite remodeling in hippocampal neurons. J. Neurosci. 2004, 24, 11473–11480.
  10. Saito, Y.; Oinuma, I.; Fujimoto, S.; Negishi, M. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. EMBO Rep. 2009, 10, 614–621.
  11. Wang, Y.; He, H.; Srivastava, N.; Vikarunnessa, S.; Chen, Y.B.; Jiang, J.; Cowan, C.W.; Zhang, X. Plexins Are GTPase-Activating Proteins for Rap and Are Activated by Induced Dimerization. Sci. Signal. 2012, 5, ra6.
  12. Uesugi, K.; Oinuma, I.; Katoh, H.; Negishi, M. Different requirement for Rnd GTPases of R-Ras GAP activity of plexin-C1 and plexin-D1. J. Biol. Chem. 2009, 284, 6743–6751.
  13. Tamagnone, L.; Artigiani, S.; Chen, H.; He, Z.; Ming, G.I.; Song, H.; Chedotal, A.; Winberg, M.L.; Goodman, C.S.; Poo, M.; et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99, 71–80.
  14. Tamagnone, L.; Comoglio, P.M. Signalling by semaphorin receptors: Cell guidance and beyond. Trends Cell Biol. 2000, 10, 377–383.
  15. Rohm, B.; Ottemeyer, A.; Lohrum, M.; Puschel, A.W. Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. Mech. Dev. 2000, 93, 95–104.
  16. Hayashi, M.; Nakashima, T.; Taniguchi, M.; Kodama, T.; Kumanogoh, A.; Takayanagi, H. Osteoprotection by semaphorin 3A. Nature 2012, 485, 69–74.
  17. Puschel, A.W. GTPases in semaphorin signaling. Adv. Exp. Med. Biol. 2007, 600, 12–23.
  18. Zanata, S.M.; Hovatta, I.; Rohm, B.; Puschel, A.W. Antagonistic effects of Rnd1 and RhoD GTPases regulate receptor activity in Semaphorin 3A-induced cytoskeletal collapse. J. Neurosci. 2002, 22, 471–477.
  19. Rajan, S.; Terman, J.R.; Reisler, E. MICAL-mediated oxidation of actin and its effects on cytoskeletal and cellular dynamics. Front. Cell Dev. Biol. 2023, 11, 1124202.
  20. Perrot, V.; Vazquez-Prado, J.; Gutkind, J.S. Plexin B regulates Rho through the guanine nucleotide exchange factors Leukemia-associated RhoGEF (LARG) and PDZ-RhoGEF. J. Biol. Chem. 2002, 278, 26111–26119.
  21. Oinuma, I.; Katoh, H.; Harada, A.; Negishi, M. Direct interaction of Rnd1 with Plexin-B1 regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell contraction in COS-7 cells. J. Biol. Chem. 2003, 278, 25671–25677.
  22. Swiercz, J.M.; Worzfeld, T.; Offermanns, S. Semaphorin 4D signaling requires the recruitment of phospholipase C gamma into the plexin-B1 receptor complex. Mol. Cell. Biol. 2009, 29, 6321–6334.
  23. Driessens, M.H.; Olivo, C.; Nagata, K.; Inagaki, M.; Collard, J.G. B plexins activate Rho through PDZ-RhoGEF. FEBS Lett. 2002, 529, 168–172.
  24. Worzfeld, T.; Swiercz, J.M.; Senturk, A.; Genz, B.; Korostylev, A.; Deng, S.; Xia, J.; Hoshino, M.; Epstein, J.A.; Chan, A.M.; et al. Genetic dissection of plexin signaling in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, 2194–2199.
  25. Shalaby, M.A.; Hampson, L.; Oliver, A.; Hampson, I. Identification of PlexinD1 and AHDC1 as a putative interactors for Tip-1 protein. Genes Genom. 2011, 33, 399–405.
  26. Kigel, B.; Rabinowicz, N.; Varshavsky, A.; Kessler, O.; Neufeld, G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood 2011, 118, 4285–4296.
  27. Takahashi, T.; Fournier, A.; Nakamura, F.; Wang, L.H.; Murakami, Y.; Kalb, R.G.; Fujisawa, H.; Strittmatter, S.M. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999, 99, 59–69.
  28. Catalano, A.; Caprari, P.; Rodilossi, S.; Betta, P.; Castellucci, M.; Casazza, A.; Tamagnone, L.; Procopio, A. Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J. 2004, 18, 358–360.
  29. Tellman, T.V.; Cruz, L.A.; Grindel, B.J.; Farach-Carson, M.C. Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration. Int. J. Mol. Sci. 2021, 22, 3218.
  30. Catalano, A.; Lazzarini, R.; Di, N.S.; Orciari, S.; Procopio, A. The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-kappaB to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells. Cancer Res. 2009, 69, 1485–1493.
  31. Yamada, D.; Watanabe, S.; Kawahara, K.; Maeda, T. Plexin A1 signaling confers malignant phenotypes in lung cancer cells. Biochem. Biophys. Res. Commun. 2016, 480, 75–80.
  32. Higgins, D.M.O.; Caliva, M.; Schroeder, M.; Carlson, B.; Upadhyayula, P.S.; Milligan, B.D.; Cheshier, S.H.; Weissman, I.L.; Sarkaria, J.N.; Meyer, F.B.; et al. Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas. BMC Cancer 2020, 20, 1213.
  33. Tian, T.V.; Tomavo, N.; Huot, L.; Flourens, A.; Bonnelye, E.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: Involvement of MMP9 and PLXNA2. Oncogene 2013, 33, 2204–2214.
  34. Yin, L.; Li, J.; Wang, J.; Pu, T.; Wei, J.; Li, Q.; Wu, B.J. MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling. Oncogene 2021, 40, 1362–1374.
  35. Shostak, K.; Zhang, X.; Hubert, P.; Goktuna, S.I.; Jiang, Z.; Klevernic, I.; Hildebrand, J.; Roncarati, P.; Hennuy, B.; Ladang, A.; et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat. Commun. 2014, 5, 5232.
  36. Toledano, S.; Sabag, A.D.; Ilan, N.; Liburkin-Dan, T.; Kessler, O.; Neufeld, G. Plexin-A2 enables the proliferation and the development of tumors from glioblastoma derived cells. Cell Death. Dis. 2023, 14, 41.
  37. Syed, V.; Zhang, X.; Lau, K.M.; Cheng, R.; Mukherjee, K.; Ho, S.M. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2005, 24, 8128–8143.
  38. Ding, H.; Li, L.; Gu, B.; Ni, Y.; Chen, S. MicroRNA-564 inhibits the progression of non-small cell lung cancer via targeting plexin A4. Exp. Ther. Med. 2021, 21, 358.
  39. Zhang, C.; Qiao, H.; Guo, W.; Liu, Y.; Yang, L.; Liu, Y.; Jin, B.; Fu, M.; Wang, G.; Li, W. CD100-Plexin-B1 induces Epithelial-Mesenchymal Transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Lett. 2019, 455, 1–13.
  40. Li, C.; Wan, L.; Wang, P.; Guan, X.; Li, C.; Wang, X. Sema4D/Plexin-B1 promotes the progression of osteosarcoma cells by activating Pyk2-PI3K-AKT pathway. J. Musculoskelet. Neuronal Interact. 2021, 21, 577–583.
  41. Peacock, J.W.; Takeuchi, A.; Hayashi, N.; Liu, L.; Tam, K.J.; Al, N.N.; Khazamipour, N.; Tombe, T.; Dejima, T.; Lee, K.C.; et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol. Med. 2018, 10, 219–238.
  42. Liu, B.; Gu, X.; Huang, T.; Luan, Y.; Ding, X. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Oncol. Rep. 2017, 37, 201–208.
  43. Ye, S.; Hao, X.; Zhou, T.; Wu, M.; Wei, J.; Wang, Y.; Zhou, L.; Jiang, X.; Ji, L.; Chen, Y.; et al. Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer 2010, 10, 611.
  44. Malik, M.F.A.; Riaz, S.K.; Waqar, S.H.; Haq, F.; Ye, L.; Jiang, W.G. Role of Plexin B1 in a Breast Cancer Cohort of Pakistani Patients and its Contribution Towards Cancer Metastasis as Indicated by an In Vitro Model. Anticancer Res. 2017, 37, 4483–4488.
  45. Argast, G.M.; Croy, C.H.; Couts, K.L.; Zhang, Z.; Litman, E.; Chan, D.C.; Ahn, N.G. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene 2009, 28, 2697–2709.
  46. Jiang, C.; Javed, A.; Kaiser, L.; Nava, M.M.; Xu, R.; Brandt, D.T.; Zhao, D.; Mayer, B.; Fernández-Baldovinos, J.; Zhou, L.; et al. Mechanochemical control of epidermal stem cell divisions by B-plexins. Nat. Commun. 2021, 12, 1308.
  47. Gurrapu, S.; Pupo, E.; Franzolin, G.; Lanzetti, L.; Tamagnone, L. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018, 25, 1259–1275.
  48. Le, A.P.; Huang, Y.; Pingle, S.C.; Kesari, S.; Wang, H.; Yong, R.L.; Zou, H.; Friedel, R.H. Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget 2015, 6, 7293–7304.
  49. Yu, W.; Goncalves, K.A.; Li, S.; Kishikawa, H.; Sun, G.; Yang, H.; Vanli, N.; Wu, Y.; Jiang, Y.; Hu, M.G.; et al. Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin. Cell 2017, 171, 849–864.
  50. Li, S.; Goncalves, K.A.; Lyu, B.; Yuan, L.; Hu, G.F. Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitors. Commun. Biol. 2020, 3, 26–0750.
  51. Yang, H.; Yuan, L.; Ibaragi, S.; Li, S.; Shapiro, R.; Vanli, N.; Goncalves, K.A.; Yu, W.; Kishikawa, H.; Jiang, Y.; et al. Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival. Br. J. Cancer 2022, 127, 422–435.
  52. Liang, Y.; Meng, K.; Qiu, R. Circular RNA Circ_0013958 Functions as a Tumor Promoter in Ovarian Cancer by Regulating miR-637/PLXNB2 Axis. Front. Genet. 2021, 12, 644451.
  53. Brundu, S.; Napolitano, V.; Franzolin, G.; Lo, C.E.; Mastrantonio, R.; Sardo, G.; Cascardi, E.; Verginelli, F.; Sarnataro, S.; Gambardella, G.; et al. Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. EMBO Mol. Med. 2023, 15, e16104.
  54. Li, X.; Law, J.W.; Lee, A.Y. Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton. Oncogene 2011, 31, 595–610.
  55. Saxena, S.; Prajapati, D.R.; Goel, P.; Tomar, B.; Hayashi, Y.; Atri, P.; Rachagani, S.; Grandgenett, P.M.; Hollingsworth, M.A.; Batra, S.K.; et al. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Cancers 2021, 13, 818.
  56. Kuhlmann, L.; Govindarajan, M.; Mejia-Guerrero, S.; Ignatchenko, V.; Liu, L.Y.; Grünwald, B.T.; Cruickshank, J.; Berman, H.; Khokha, R.; Kislinger, T. Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. J. Proteome Res. 2022, 21, 2224–2236.
  57. Scott, G.A.; McClelland, L.A.; Fricke, A.F.; Fender, A. Plexin C1, A Receptor for Semaphorin 7A, Inactivates Cofilin and Is a Potential Tumor Suppressor for Melanoma Progression. J. Investig. Dermatol. 2009, 129, 954–963.
  58. Zhao, X.; Wang, P.; Liu, J.; Zheng, J.; Liu, Y.; Chen, J.; Xue, Y. Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222. Mol. Ther. 2015, 23, 1899–1911.
  59. Ma, B.; Herzog, E.L.; Lee, C.G.; Peng, X.; Lee, C.M.; Chen, X.; Rockwell, S.; Koo, J.S.; Kluger, H.; Herbst, R.S.; et al. Role of Chitinase 3-like-1 and Semaphorin 7A in Pulmonary Melanoma Metastasis. Cancer Res. 2014, 75, 487–496.
  60. Chen, J.; Liu, H.; Chen, J.; Sun, B.; Wu, J.; Du, C. PLXNC1 Enhances Carcinogenesis Through Transcriptional Activation of IL6ST in Gastric Cancer. Front. Oncol. 2020, 10, 33.
  61. Casazza, A.; Finisguerra, V.; Capparuccia, L.; Camperi, A.; Swiercz, J.M.; Rizzolio, S.; Rolny, C.; Christensen, C.; Bertotti, A.; Sarotto, I.; et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J. Clin. Investig. 2010, 120, 2684–2698.
  62. Casazza, A.; Kigel, B.; Maione, F.; Capparuccia, L.; Kessler, O.; Giraudo, E.; Mazzone, M.; Neufeld, G.; Tamagnone, L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol. Med. 2012, 4, 234–250.
  63. Luchino, J.; Hocine, M.; Amoureux, M.C.; Gibert, B.; Bernet, A.; Royet, A.; Treilleux, I.; Lecine, P.; Borg, J.P.; Mehlen, P.; et al. Semaphorin 3E Suppresses Tumor Cell Death Triggered by the Plexin D1 Dependence Receptor in Metastatic Breast Cancers. Cancer Cell 2013, 24, 673–685.
  64. Man, J.; Shoemake, J.; Zhou, W.; Fang, X.; Wu, Q.; Rizzo, A.; Prayson, R.; Bao, S.; Rich, J.N.; Yu, J.S. Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 2014, 9, 1812–1826.
  65. Liu, H.; Juo, Z.S.; Shim, A.H.; Focia, P.J.; Chen, X.; Garcia, K.C.; He, X. Structural Basis of Semaphorin-Plexin Recognition and Viral Mimicry from Sema7A and A39R Complexes with PlexinC1. Cell 2010, 142, 749–761.
  66. Odabas, G.; Cetin, M.; Turhal, S.; Baloglu, H.; Sayan, A.E.; Yagci, T. Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma. Can. J. Gastroenterol. Hepatol. 2018, 2018, 4040787.
  67. NazimTurhal, S.; Dogan, M.; Esendagli, G.; Artac, M.; Korkmaz, L.; Coskun, H.S.; Goker, E.; PerranYumuk, F.; Bilgetekin, I.; Kose, F.; et al. The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: A Turkish Oncology Group (TOG) Study. J. Gastrointest. Cancer 2021, 53, 356–362.
  68. Ni, Z.; Huang, C.; Zhao, H.; Zhou, J.; Hu, M.; Chen, Q.; Ge, B.; Huang, Q. PLXNC1: A Novel Potential Immune-Related Target for Stomach Adenocarcinoma. Front. Cell Dev. Biol. 2021, 9, 662707.
  69. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep. 2014, 6, 13.
  70. Roodink, I.; Raats, J.; Van Der, Z.B.; Verrijp, K.; Kusters, B.; Van Bokhoven, H.; Linkels, M.; de Waal, R.M.; Leenders, W.P. Plexin d1 expression is induced on tumor vasculature and tumor cells: A novel target for diagnosis and therapy? Cancer Res. 2005, 65, 8317–8323.
  71. Vivekanandhan, S.; Mukhopadhyay, D. Divergent roles of Plexin D1 in Cancer. Biochim. Biophys. Acta Rev. Cancer 2019, 1872, 103–110.
  72. Gu, C.; Yoshida, Y.; Livet, J.; Reimert, D.V.; Mann, F.; Merte, J.; Henderson, C.E.; Jessell, T.M.; Kolodkin, A.L.; Ginty, D.D. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307, 265–268.
  73. Yang, W.J.; Hu, J.; Uemura, A.; Tetzlaff, F.; Augustin, H.G.; Fischer, A. Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis. EMBO Mol. Med. 2015, 20, 1267–1284.
  74. Smolkin, T.; Nir-Zvi, I.; Duvshani, N.; Mumblat, Y.; Kessler, O.; Neufeld, G. Complexes of plexin-A4 and plexin-D1 convey semaphorin-3C signals to induce cytoskeletal collapse in the absence of neuropilins. J. Cell Sci. 2018, 131, jcs208298.
  75. Mumblat, Y.; Kessler, O.; Ilan, N.; Neufeld, G. Full length semaphorin-3C functions as an inhibitor of tumor lymphangiogenesis and tumor metastasis. Cancer Res. 2015, 75, 2177–2186.
  76. Bassi, D.E.; Fu, J.; de Lopez, C.R.; Klein-Szanto, A.J. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol. Carcinog. 2005, 44, 151–161.
  77. Shalaby, M.A.; Hampson, L.; Oliver, A.; Hampson, I. Plexin d1: New potential biomarker for cervical cancer. J. Immunoass. Immunochem. 2012, 33, 223–233.
More
Information
Subjects: Cell Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : ,
View Times: 518
Revisions: 2 times (View History)
Update Date: 24 Aug 2023
1000/1000
ScholarVision Creations